ABSTRACT
Clinical trial data are now sufficient to support aggressive treatment of dyslipidemia. Cholesterol-lowering therapy is known to reduce the risk of clinical events across a wide range of lipid levels, even in patients with "normal" levels. Current data support lowering low-density lipoprotein cholesterol (LDL-C) levels at least to those recommended by the National Cholesterol Education Program, but perhaps even more aggressively in some patients. Of the available cholesterol-lowering agents, statins produce the greatest reductions in LDL-C levels and coronary events and are currently the best treatment option for most patients.
Footnotes
↵* The author has received grant or research support from, has acted as a consultant for, and has been on the speakers’ bureau of the Parke-Davis/Pfizer, Merck, Bayer, Novartis, Astra-Zeneca, and Schering-Plough corporations.
- Copyright © 2001 The Cleveland Clinic Foundation. All Rights Reserved.